Avenue Therapeutics Inc (ATXI)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Avenue Therapeutics Inc chart...

About the Company

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Exchange

NASDAQ

Website

http://www.avenuetx.com/

$532M

Total Revenue

11

Employees

$1M

Market Capitalization

-3.05

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ATXI News

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

9h ago, source:

Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in ...

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

3d ago, source:

Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and ...

Avenue Therapeutics granted extension for Nasdaq compliance

on MSN ago, source:

Avenue Therapeutics (NASDAQ:ATXI) has announced that, the Nasdaq Hearings Panel granted the Co.’s request for an extension to evidence compliance with all applicable criteria for continued listing on ...

Third suspect charged with second-degree murder in connection to killing of 18-year-old man on Lakeside Avenue

15h ago, source: WRIC on MSN

A third suspect has been arrested and charged with second-degree murder in connection to the shooting death of a man that ...

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

7d ago, source: Yahoo Finance

MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty ...

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

21h ago, source: Business Insider

CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial ... Abeona entered a $50 million credit facility with the Avenue Venture Opportunities ...

Road projects along Wakulla Arran Road and Songbird Avenue in Crawfordville: Here's what you should know

8h ago, source: WTXL ABC 27

Road projects get underway along two roads in Crawfordville. Neighbors react to those updates involving Songbird Avenue and ...

Project set to fix Bristol Avenue bottleneck in Walker

12h ago, source: WOOD-TV on MSN

Construction will start soon on a longtime headache for drivers in Walker: The Bristol Avenue railroad bridge.

Westover wants Holland Avenue commitment from DOH

2h ago, source:

The West Virginia Division of Highways no longer intends to resurface Holland Avenue as the final phase of Westover's project addressing stormwater and sewer lines beneath the crumbing road. Instead, ...

Gain Therapeutics to Present at Public Ventures Discovery Day

3d ago, source:

Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, (NASDAQ: MDBH), is the first invite-only investor community and self-clearing broker-dealer platform dedicated to backing ...

Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

16h ago, source: Finanznachrichten

CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial ... Abeona entered a $50 million credit facility with the Avenue Venture Opportunities ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...